Switching Because of Treatment Intolerance
Treatment intolerance suggests that a treatment is still controlling the disease, but its side effects make it difficult or unsafe to continue. Depending on the type and severity of the side effects, your doctor may first consider supportive care, a temporary treatment interruption, or a dose adjustment prior to switching.
When intolerance is the reason for a change, in some cases, switching to another therapy that works in a similar way may allow you to maintain disease control while seeking a more manageable treatment experience.
One possible advantage of staying within the same class of medication is that it may preserve more treatment options for later. Because there are a limited number of treatment classes available for CLL/SLL, using a different class now means that class may not be available in the future. By staying within the same class when the reason for discontinuation is side effects rather than disease progression, you may keep other classes of treatment in reserve.
Changing Treatment Because of Disease Progression
Disease progression means that the CLL/SLL is growing or becoming more active despite treatment. Progression may be identified through changes in symptoms, physical findings, blood counts, or other clinical assessments.
When the disease progresses during treatment, it may indicate that the current therapy is no longer effective to control the CLL/SLL. In this situation, your healthcare team may recommend a treatment with a different approach or mechanism.
Progression does not always mean that a new treatment must begin immediately. Your doctor will consider whether the disease requires further treatment by using additional information such as current symptoms, test results, symptoms, prior therapies, overall health, and personal preferences.
Switching Among BTK Inhibitors
BTK inhibitors are an established treatment option for CLL/SLL. However, treatments within this class are not interchangeable. They may differ in how selectively they target BTK, the clinical evidence supporting disease control, and their side-effect profiles.
It is important to distinguish treatment intolerance from disease progression. Treatment intolerance means that a treatment may still be controlling the CLL/SLL, but its side effects make it difficult or unsafe to continue. Disease progression means that the CLL/SLL is becoming more active despite treatment. The reason the previous treatment ended can affect whether another treatment in the same class or a treatment with a different mechanism may be appropriate.
When side effects—not disease progression—are the reason for stopping treatment, another BTK inhibitor may allow some patients to continue receiving BTK-targeted therapy. Prospective clinical research has shown that many patients who switched because of intolerance did not experience a recurrence of the same treatment-limiting side effect, although previous side effects can recur and new side effects can develop.
When considering another BTK inhibitor, ask whether the available options have been compared directly in people with CLL/SLL. Several randomized head-to-head clinical trials found meaningful differences between treatments in this class, including differences in how long the disease remained controlled and in the occurrence of certain heart-related side effects.
These findings do not mean that one treatment is appropriate for every person. They do mean that the choice should consider evidence for both disease control and tolerability rather than assuming that all BTK inhibitors provide the same results.
Because BTK-inhibitor therapy is commonly continued until the disease progresses or side effects become unacceptable, the ability to tolerate and remain on treatment can be an important part of its overall benefit.
Your healthcare team may consider:
- Evidence from clinical trials
- How long each option has been shown to control CLL/SLL
- The likelihood of heart-rhythm problems, high blood pressure, bleeding, infections, or other side effects
- Whether a side effect experienced with the previous treatment is likely to recur
- Your heart health, bleeding risk, other medical conditions, and current medications
- Potential drug-to-drug interactions
- How the dosing schedule may fit a daily routine
- How often monitoring or treatment interruptions may be needed
No single factor determines the best treatment. The goal is to select a treatment with evidence of effective disease control and a safety and dosing profile that fits your individual health needs and treatment priorities.
BTK inhibitors can cause bleeding, infections, diarrhea, headache, muscle or joint pain, high blood pressure, and heart-rhythm problems. The type and frequency of side effects may differ among treatments and from person to person.
Tell your healthcare team about any new, persistent, or worsening symptoms, even if they seem minor. Depending on the symptom and its severity, your doctor may recommend supportive care, closer monitoring, adjusting or stopping current treatment, or a change in treatment.
Switching after treatment discontinuation does not guarantee that a previous side effect will go away or that new side effects will not occur. The right treatment decision depends on your symptoms, medical history, other medications, treatment goals, and how your CLL/SLL is responding.
Do not stop or adjust your medication without speaking with your healthcare team. Your doctor can help determine whether your side effects can be managed or whether another treatment approach should be considered.
Questions to Ask Your Doctor
- Is my treatment being changed because of side effects, disease progression, or both?
- Is the disease still responding to my current treatment?
- If side effects are the reason for switching, could another BTK inhibitor allow me to continue this type of treatment?
- How do the treatments compare in their ability to provide lasting disease control?
- How do they compare in heart-rhythm problems, high blood pressure, bleeding, infections, and treatment discontinuation?
- How likely is my previous side effect to recur after switching?
- Which option best fits my cardiovascular health, other medical conditions, and current medications?
- How would the dosing schedule affect my daily routine?
- How will the switch be planned and monitored?
